State of the Industry A view from the West David Thomas Director, - - PowerPoint PPT Presentation

▶
state of the industry
SMART_READER_LITE
LIVE PREVIEW

State of the Industry A view from the West David Thomas Director, - - PowerPoint PPT Presentation

Feb 25, 2023 235 likes •376 views

State of the Industry A view from the West David Thomas Director, Industry Research & Analysis BIO BIO Europe Spring March 11, 2013 1 BIOTECHNOLOGY INDUSTRY ORGANIZATION PRESENTATION TITLE IN FOOTER MONTH XX, 2012 U.S. IPOs:

slide-1
SLIDE 1

BIOTECHNOLOGY INDUSTRY ORGANIZATION PRESENTATION TITLE IN FOOTER MONTH XX, 2012

1

David Thomas

Director, Industry Research & Analysis BIO BIO Europe Spring March 11, 2013

State of the Industry

A view from the West

slide-2
SLIDE 2

U.S. IPOs: Returning to “Normal”?

Source: Factset, BIO Industry Analysis, March 6, 2013

Performance

Since IPO Date 2009 2010 2011 2012 2013 CLASS:

3 (3) 17 (12) 13 (8) 13 (11) 3 (2)

Total # (therapeutic #):

slide-3
SLIDE 3

1994 2000 2005 2010 2013

20 YEARS OF BIOTECH

(Nasdaq Biotechnology Index, NBI)

Source: Factset, BIO Industry Analysis, March 6, 2013

1580 1611

slide-4
SLIDE 4

Source: Factset, BIO Industry Analysis, March 6, 2013

Performance

Since IPO Date

Amount

Raised vs Filed 2009 2010 2011 2012 2013 CLASS:

U.S. IPOs: Returning to “Normal”?

slide-5
SLIDE 5

Fewer Pipeline Acquisitions

Pipeline Acquisitions $>10M

Source: BIO Industry Analysis, Elsevier Database, March 2013

slide-6
SLIDE 6

Fewer Pipeline Acquisitions

Pipeline Acquisitions $>10M Pipeline Alliances $>10M

Fewer Pipeline Alliances

Source: BIO Industry Analysis, Elsevier Database, March 2013

slide-7
SLIDE 7

Source: BIO Industry Analysis, Elsevier Database, February 2013

M&A: BIOBUCK Breakout in 2012!

Private Company Acquisitions >$10M

slide-8
SLIDE 8

Good news for VCs:

Expanding multiples on upfronts

Source: HBM Partners, January 2013

3.1 3.2 3.4 3.5 5.1 3.7 4.6 6.2 1.6 2.0 1.8 1.5 2.0 1.0 2.5 3.5

1 2 3 4 5 6 7

2005 2006 2007 2008 2009 2010 2011 2012

Multiple

Total Deal Value/Invested Capital Median Multiple on Upfront

slide-9
SLIDE 9

Time to Pharma Acquisition: Getting Longer and Longer

Source: HBM Partners, January 2013

slide-10
SLIDE 10

Venture: Pharma to the Rescue?

Source: BIO Industry Analysis, BioCentury’s BCIQ, March 2013

slide-11
SLIDE 11

Pharma VC backing: A Higher Step-Up at M&A

N=24 N=84 Average Step-Up at Acquisition

Source: Elsevier’s Start-Up, October 2012

slide-12
SLIDE 12

Breakouts Everywhere!

Source: BIO Industry Analysis, March 2013

  • Biotech Index
  • FDA Approvals
  • Orphan Indication Approvals
  • IPO performance
  • Big Earnout structures
  • Step-ups on VC acquisition exits
  • Corporate Venture Capital
slide-13
SLIDE 13

BIOTECHNOLOGY INDUSTRY ORGANIZATION PRESENTATION TITLE IN FOOTER MONTH XX, 2012

13

www.BIOtech-now.org